<DOC>
	<DOCNO>NCT02319603</DOCNO>
	<brief_summary>A randomized , double-blind , two dose group , parallel-control multi-center , post-marketing clinical trial，to evaluate efficacy safety Wenxin keli treat atrial premature beat different dose , provide scientific basis rational clinical use drug .</brief_summary>
	<brief_title>To Evaluate Efficacy Safety Wenxin Keli Treating Atrial Premature Beats</brief_title>
	<detailed_description>Research purpose： To evaluate efficacy safety Wenxin keli treat atrial premature beat different dose , provide scientific basis rational clinical use drug . Research design： A randomized , double-blind , two dose group , parallel-control multi-center , post-marketing clinical trial . Sample size : A total 288 subject , 144cases group . Therapeutic schedule : 1 . Low dose group ( original quantity Wenxin keli ) : specification 10g /bag , Wenxin keli ( sugar ) 5 g+ Wenxin keli simulation agent 5g . 2 . High dose group ( 2 time amount Wenxin keli ) : specification 10g /bag , Wenxin keli ( sugar ) 10 g. Usage Dosage : Oral ,1bag time , 3 time day , 4 week 1 course treatment . Drug combination : During test shall merge anti-arrhythmic drug beyond provision scheme . Due merger disease condition change , use drug treatment , investigator must record type ( treatment ) , drug usage , time reason , order summarize , analyze report . Primary indicator : 24 h dynamic electrocardiogram ( Holter ) : treatment , treatment 4 w , record time . Secondary Indicator : Symptom score : treatment , treatment 4 w , record time . Security index : 1 . Vital sign : treatment , treatment 4 w , record time . 2 . Blood , urine , stool occult blood , liver kidney function , blood coagulation four , electrolyte examination , electrocardiogram ( ecg ) : treatment , treatment 4 w , record time . Main efficacy : Holter efficient curative effect ( main efficacy index ) Effective : premature beat frequency reduce 50 % take medicine . Invalid : effective standard . Secondary efficacy : Symptom score curative effect Effective : symptom improve symptom ( drop 1or ) Invalid : effective standard . Statistic analysis : Main efficacy index mean FAS , PPS analysis , safety index SS set analysis .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Cardiac Complexes , Premature</mesh_term>
	<mesh_term>Atrial Premature Complexes</mesh_term>
	<criteria>Accord diagnostic criterion arrhythmia ( atrial premature beat ) The average number premature beat 24 h dynamic electrocardiogram &gt; 360 times/h ( effective record least 22 h ) Stop use anti arrhythmic drug five halflife ( except longterm ( one month ) beta blocker high blood pressure exertional angina ) Ages 18 75 year old , gender Voluntary subject sign informed consent form Need merge antiarrhythmic drug ( Ⅰ , Ⅱ , Ⅲ , Ⅳ ) serious condition Heart rhythm disorder cause factor drug , electrolyte acidbase balance disorder Merge tardy arrhythmia ( include sick sinus syndrome Ⅱdegree atrioventricular block ) Patients heart percutaneous coronary intervention ( PCI ) coronary artery bypass grafting ( CABG ) surgery Patients severe hypotension With serious cardiovascular disease ( severe coronary heart disease , congenital heart disease , cardiomyopathy , myocardial infarction , congestive heart failure , cardiac shock , etc . ) , cerebrovascular disease , severe respiratory disease ( chronic obstructive pulmonary disease , pulmonary hypertension , pulmonary embolism , etc . ) , serious primary disease liver , kidney hematopoietic system ( ALT , AST , BUN 2 time higher normal ceiling , Cr high upper limit normal ) Allergic constitution ; test drug allergy ingredient elements allergy Pregnancy lactation woman , recent preparation pregnancy With chronic alcoholism , drug dependence , mental illness Participated clinical trial within 3 month Patients think investigator suitable participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>